Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,078 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL, Mesa RA, Dunn WG, Nadezhdin E, Curto-Garcia N, Green A, Wilkins B, Coppell J, Laurie J, Garg M, Ewing J, Knapper S, Crowe J, Chen F, Koutsavlis I, Godfrey A, Arami S, Drummond M, Byrne J, Clark F, Mead-Harvey C, Baxter EJ, McMullin MF, Mead AJ. Harrison CN, et al. Among authors: jackson a. J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1. J Clin Oncol. 2023. PMID: 37126762 Free PMC article. Clinical Trial.
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.
Appleby N, Eyre TA, Cabes M, Jackson A, Boucher R, Yates F, Fox S, Rawstron A, Hillmen P, Schuh A. Appleby N, et al. Among authors: jackson a. BMC Cancer. 2019 May 20;19(1):471. doi: 10.1186/s12885-019-5717-y. BMC Cancer. 2019. PMID: 31109313 Free PMC article. Clinical Trial.
De-Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromes.
Killick S, Jackson A, Coulthard HC, Yap C, Das-Gupta E, Pennell DJ, Porter J, Bowen D, Culligan D. Killick S, et al. Among authors: jackson a. Br J Haematol. 2020 Jun;189(6):e237-e240. doi: 10.1111/bjh.16669. Epub 2020 Apr 27. Br J Haematol. 2020. PMID: 32342485 Free article. Clinical Trial. No abstract available.
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, Andrew G, Nagra S, Malladi R, Peniket A, Gilleece M, Salim R, Tholouli E, Potter V, Crawley C, Wheatley K, Protheroe R, Vyas P, Hunter A, Parker A, Wilson K, Pavlu J, Byrne J, Dillon R, Khan N, McCarthy N, Freeman SD. Craddock C, et al. Among authors: jackson a. J Clin Oncol. 2021 Mar 1;39(7):768-778. doi: 10.1200/JCO.20.02308. Epub 2020 Dec 29. J Clin Oncol. 2021. PMID: 33373276 Free PMC article. Clinical Trial.
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
Loke J, Metzner M, Boucher R, Jackson A, Hopkins L, Pavlu J, Tholouli E, Drummond M, Peniket A, Bishop R, Fox S, Vyas P, Craddock C. Loke J, et al. Among authors: jackson a. Br J Haematol. 2022 Jan;196(2):368-373. doi: 10.1111/bjh.17823. Epub 2021 Sep 6. Br J Haematol. 2022. PMID: 34490623 Free article.
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
Sternberg A, Boucher R, Coulthard HC, Raghavan M, Culligan D, Jackson A, Cargo C, Dennis M, Metzner M, O'Sullivan J, Moore R, Bowen D, Vyas P. Sternberg A, et al. Among authors: jackson a. Br J Haematol. 2022 Oct;199(2):222-229. doi: 10.1111/bjh.18389. Epub 2022 Aug 2. Br J Haematol. 2022. PMID: 35918828 Clinical Trial.
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.
Fang Z, Corbizi Fattori G, McKerrell T, Boucher RH, Jackson A, Fletcher RS, Forte D, Martin JE, Fox S, Roberts J, Glover R, Harris E, Bridges HR, Grassi L, Rodriguez-Meira A, Mead AJ, Knapper S, Ewing J, Butt NM, Jain M, Francis S, Clark FJ, Coppell J, McMullin MF, Wadelin F, Narayanan S, Milojkovic D, Drummond MW, Sekhar M, ElDaly H, Hirst J, Paramor M, Baxter EJ, Godfrey AL, Harrison CN, Méndez-Ferrer S. Fang Z, et al. Among authors: jackson a. Nat Commun. 2023 Nov 25;14(1):7725. doi: 10.1038/s41467-023-43175-5. Nat Commun. 2023. PMID: 38001082 Free PMC article. Clinical Trial.
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.
McIlroy G, Lax S, Gaskell C, Jackson A, Rhodes M, Seale T, Fox S, Hopkins L, Okosun J, Barrington SF, Ringshausen I, Ramsay AG, Calaminici M, Linton K, Bishton M. McIlroy G, et al. Among authors: jackson a. BMC Cancer. 2024 Mar 25;24(1):370. doi: 10.1186/s12885-024-12112-0. BMC Cancer. 2024. PMID: 38528445 Free PMC article.
Reply to G. Gui et al.
Craddock C, Jackson A, Freeman SD. Craddock C, et al. Among authors: jackson a. J Clin Oncol. 2021 Jul 20;39(21):2416-2417. doi: 10.1200/JCO.21.00603. Epub 2021 May 5. J Clin Oncol. 2021. PMID: 33950696 No abstract available.
5,078 results